Newsroom

Targeted Oncology First Patient With VEGFRi-Associated Hand-Foot Skin Reaction Enrolled in NOVA-II

Jordyn Sava November 10, 2022 Part 2 of the NOVA-II phase 2 trial evaluating OQL011 has enrolled the first patient with cancer with...

Nov 10, 2022

November 9, 2022 The key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal...

Nov 9, 2022

Hosted by Jingyi Liu August 3, 2022 Hong Tang Biography Dr. Hong Tang is Chief Medical Officer, and co-founder of OnQuality...

Aug 3, 2022

Hosted by Joe Varriale June 30, 2022 Hong Tang is the co-founder and Chief Medical Officer of OnQuality Pharmaceuticals, a targeted...

Jun 30, 2022

Written by Max Bayer June 15, 2022 Six days after the World Health Organization officially declared COVID-19 a global pandemic on March...

Jun 15, 2022

Source: https://www.biospectrumasia.com/e-magazine By Dr. Manbeena Chawla June 2022 Although there has been tremendous progress in...

Jun 1, 2022

Source: https://brilliancewithincoaching.com/podcast/leading-without-the-title-becoming-a-natural-leader-with-hong-tang/ Hong Tang is the...

May 17, 2022

High Hopes In COVID-19, Cancer, CNS, Immunology And Rare Disease By Eleanor Malone March 1, 2022 Executive Summary Evolving challenges...

Mar 1, 2022

Written by Alex Philippidis February 2, 2022 OnQuality recently announced positive news for its lead candidate OQL011, an ointment...

Feb 2, 2022

Written by Michael McCullar, Ph.D. Feb. 1, 2022 The ability to differentiate in a competitive marketplace lies in developing key...

Feb 1, 2022